Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by NDIKUYEZE, A.
Right arrow Articles by POLK, B F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NDIKUYEZE, A.
Right arrow Articles by POLK, B F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 Oxford University Press

research-article

Immunogenicity and Safety of Measles Vaccine in III African Children

ANDRE NDIKUYEZE*, ALVARO MUNOZ{dagger}, JOHN STEWART{ddagger}, JOHN MODLIN{dagger},§, DAVID HEYMANN{ddagger}, KENNETH L HERRMANN{ddagger} and B FRANK POLK{dagger},

*National University of Rwanda Butare, Rwanda
{dagger}Department of Epidemiology, Johns Hopkins School of Hygiene and Public Health 615 N Wolfe Street, Baltimore, MA 21205, USA
{ddagger}Center for Infectious Diseases, Centers for Disease Control, Public Health Service, US Department of Health and Human Services Atlanta, USA
§Department of Pediatrics, Johns Hopkins School of Medicine Baltimore, USA

Reprint requests to: Dr Polk.

A concurrent prospective study was conducted in Rwanda to compare the Immunogenicity and safety of live, attenuated measles vaccine in ill and well children. Five hundred and eighteen children aged 8 to 19 months were selected from children attending the acute care and immunization services of two clinics. Two hundred and sixty-seven ill children and 251 well children were enrolled and examined. Serological tests were performed on blood samples obtained before and 40 days after measles immunization. Among the 208 ill children and 215 well children who were seronegative at baseline and had unequivocal follow-up serological results, seroconversion rates were 81% and 80%, respectively. Side effects were modest and were equally frequent in the two study groups (15.4% among ill children versus 15.1% among well children).

These results support a change in measles immunization policy in developing countries with respect to immunization of children with acute illnesses. Such a change would make a great contribution to decreasing the enormous burden of measles in the developing world through increased immunization coverage.

Revised 1 April 1987


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.